小骨瓣开颅血肿清除术治疗高血压性小脑出血临床疗效观察

目的:探讨小骨瓣开颅血肿清除术治疗高血压性小脑出血的临床疗效.方法:回顾性分析23例急诊小骨瓣开颅血肿清除术治疗高血压性小脑出血患者的临床资料,依据患者术后复查CT及术后1个月、3个月随访的GOS评价手术疗效.结果:本组均在术后24 h内复查头部CT,其中完全清除血肿22例,部分清除血肿1例(血肿残余量＜10％),术后1个月GOS:5分20人,4分3人;术后3个月GOS:5分22人,4分1人.结论:高血压性小脑出血的"小骨瓣开颅血肿清除术"具有创伤小、手术时间短、并发症少、术后患者恢复快、愈后好等特点,值得推广应用.     

小骨瓣开颅血肿清除术治疗高血压性小脑出血临床疗效观察

目的:探讨小骨瓣开颅血肿清除术治疗高血压性小脑出血的临床疗效.方法:回顾性分析23例急诊小骨瓣开颅血肿清除术治疗高血压性小脑出血患者的临床资料,依据患者术后复查CT及术后1个月、3个月随访的GOS评价手术疗效.结果:本组均在术后24 h内复查头部CT,其中完全清除血肿22例,部分清除血肿1例(血肿残余量＜10％),术后1个月GOS:5分20人,4分3人;术后3个月GOS:5分22人,4分1人.结论:高血压性小脑出血的"小骨瓣开颅血肿清除术"具有创伤小、手术时间短、并发症少、术后患者恢复快、愈后好等特点,值得推广应用.     

小骨窗脑室镜下血肿清除术治疗高血压性脑出血42例疗效观察

目的探讨小骨窗脑室镜下颅内血肿清除术治疗早期高血压性脑出血的临床疗效。方法对42例早期高血压性脑出血患者采用小骨窗脑室镜下颅内血肿清除术治疗,统计术后1周血肿清除率和术后3个月进行GOS评分,评估疗效。结果 42例患者顺利通过手术。术后1周复查血肿清除≥90%者31例,50%～90%者11例。术后GOS评分,优13例,良21例,优良率为81.0%,死亡2例,死亡率为4.8%。结论小骨窗脑室镜下颅内血肿清除术治疗早期高血压性脑出血,创伤小,操作简单,临床疗效满意,有临床推广价值。     

小骨窗开颅术治疗高血压脑出血45例分析

目的 比较小骨窗开颅血肿清除术与传统开颅手术治疗高血压脑出血的疗效.方法 对78例高血压脑出血患者分别采用小骨窗开颅术及传统开颅手术治疗,比较2种手术方法疗效.结果 2组无论在病死率、术后神经功能KPS评分及术后3个月患者GOS评分方面差异均有统计学意义.结论 小骨窗开颅术的手术病死率与致残率,以及预后的改善情况,优于传统开颅组.是目前治疗Glasgow昏迷评分≥6分的高血压脑出血的理想微创治疗方法.     

高血压脑室出血手术治疗25例临床分析

目的:探讨原发性高血压性脑室出血的手术方法。方法:采用开颅血肿清除术伴腰池脑脊液外引流治疗25例原发性高血压脑室出血患者,观察术后3个月格拉斯哥预后评分(GOS)。结果:术后3个月随访,GOS评分5分7例,4分5例,3分8例,2分3例,1分2例。结论:开颅血肿清除术伴腰池脑脊液外引流是治疗高血压脑室出血的有效方法。     

内镜辅助小骨窗开颅术与微创颅内血肿清除术治疗高血压脑出血临床对照研究

目的评价微创术和小骨窗开颅手术治疗高血压脑出血的疗效。方法随机选择经头颅CT确诊的高血压脑出血病人50例,分2组进行对照研究,行小骨窗开颅手术25例,行颅内血肿微创清除术25例。结果微创颅内血肿清除术速度快,小骨窗开颅血肿清除术清除血肿较彻底,但从术后并发症比较2组无显著性差异,2组术后6个月的GOS评分情况无显著性差异。结论小骨窗开颅术与微创颅内血肿清除术治疗高血压脑出血都是行之有效的手术方法,2者对预后有相似的结果。     

方体定向置软管血肿排空术治疗高血压小脑出血23例分析

目的 总结高血压性小脑出血微创手术治疗经验.方法 对2010年06月1～2011年12月我院收治的23例高血压性小脑出血患者行方体定向置软管血肿排空术,观察、分析手术疗效.结果 所有病例血肿均一次穿刺成功,平均手术时间35～45min,引流管在术后2～5天拔除.术后有1例发生再出血,无颅内感染发生.术后随访3个月,GOS评分:5分(恢复良好)18例,4分(轻度残疾)4 例,3分(重度残疾)1例,无植物生存及死亡病例.结论 方体定向置软管血肿排空术是一种具有安全、微创、高效、快速、出血少等特点的高血压小脑出血微创手术方法.     

手术放大镜辅助超早期经侧裂入路清除高血压基底节区脑出血

目的 探讨手术放大镜辅助下超早期行侧裂入路清除高血压基底节脑出血的疗效. 方法 对37例入院时神志不清的高血压基底节脑出血患者实施急诊血肿清除手术,手术在眼镜式手术放大镜辅助下进行,经侧裂入路清除血肿,常规去骨瓣减压,总结手术效果及术后生活质量. 结果 术后第2天复查头颅CT提示,30例患者清除血肿达90％以上,7例患者清除血肿达85％以上.37例患者中术后出现一侧肢体偏瘫29例,完全失语2例,言语含糊2例,记忆力障碍1侧,有2例出现情绪低落.出现肺部感染10例,3例出现消化道出血,有1例患者因术后再出血脑疝死亡.术3月随访,GOS评分5分11例,4分18例,3分5例,2分2例. 结论 眼镜式手术放大镜辅助经侧裂入路清除基底节脑内血肿可以最大程度减少对正常脑组织的破坏,是清除高血压基底节脑出血的理想方法.     

脑出血显微手术治疗的个体化策略及疗效分析

目的:探讨脑出血显微手术治疗的个体化策略选择、手术体会及临床效果。方法:回顾分析2011年11月~2014年10月我科接受显微手术治疗的脑出血患者的相关临床资料。结果:63例患者中有58例患者血肿达到基本清除,出院时根据GOS评分,恢复良好(GOS评分5分)9例,中度残疾(GOS评分4分)28例,重度残疾(GOS评分3分)19例,植物状态(GOS评分2分)5例,死亡(GOS评分1分)2例。结论:脑出血的显微手术治疗应根据患者的状况及出血部位,制定个体化的手术策略,以达到脑组织的最大保护,减少手术损伤,同时能更好地清除血肿及止血,促进患者的术后康复。     

显微镜下开颅血肿清除术治疗高血压脑出血

目的:探讨显微镜下开颅血肿清除术治疗高血压脑出血的临床效果。方法:回顾性分析本科2009年5月-2014年5月收治253例高血压脑出血患者施行显微镜下开颅血肿清除术的临床资料,其中常规开颅去骨瓣减压血肿清除术68例,小骨窗开颅血肿清除术185例。结果:所有患者术后24 h复查CT,血肿完全清除119例,残留血肿量≤10 m L者87例,10 m L<残留血肿量≤20 m L者46例,1例残留血肿量25 m L。术后6个月根据GOS量表恢复评定,5分71例,4分95例,3分55例,2分24例,1分8例。结论:高血压脑出血一般采用传统的非手术治疗,在出血严重的情况下需采取手术治疗,准确掌握手术适应证、显微操作技巧、手术时机及处理好术后各种术后并发症,是减少死亡率和提高患者生存率的重要手段。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…